Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/8642
ANTIMALARIAL ACTIVITY OF POTENTIAL INHIBITORS OF PLASMODIUM FALCIPARUM LACTATE DEHYDROGENASE ENZYME SELECTED BY DOCKING STUDIES
Antimalarials/therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemistry
Itraconazole/pharmacology
Author
Affilliation
Universidade Federal de Minas Gerais. Faculdade de Medicina. Belo Horizonte, MG, Brazil/Fundação Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratório de Malária. Belo Horizonte, MG, Brazil
Military Institute of Engineering Defense. Laboratory of Molecular Modeling Applied to the Chemical and Biological. Rio de Janeiro, RJ, Brazil
Military Institute of Engineering Defense. Laboratory of Molecular Modeling Applied to the Chemical and Biological. Rio de Janeiro, RJ, Brazil
Military Institute of Engineering Defense. Laboratory of Molecular Modeling Applied to the Chemical and Biological. Rio de Janeiro, RJ, Brazil
Universidade Federal de Minas Gerais. Faculdade de Medicina. Belo Horizonte, MG, Brazil/Fundação Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratório de Malária. Belo Horizonte, MG, Brazil,
Military Institute of Engineering Defense. Laboratory of Molecular Modeling Applied to the Chemical and Biological. Rio de Janeiro, RJ, Brazil
Military Institute of Engineering Defense. Laboratory of Molecular Modeling Applied to the Chemical and Biological. Rio de Janeiro, RJ, Brazil
Military Institute of Engineering Defense. Laboratory of Molecular Modeling Applied to the Chemical and Biological. Rio de Janeiro, RJ, Brazil
Universidade Federal de Minas Gerais. Faculdade de Medicina. Belo Horizonte, MG, Brazil/Fundação Oswaldo Cruz. Centro de Pesquisas Rene Rachou. Laboratório de Malária. Belo Horizonte, MG, Brazil,
Abstract
The Plasmodium falciparum lactate dehydrogenase enzyme (PfLDH) has been considered as a potential molecular target for antimalarials due to this parasite's dependence on glycolysis for energy production. Because the LDH enzymes found in P. vivax, P. malariae and P. ovale (pLDH) all exhibit ∼90% identity to PfLDH, it would be desirable to have new anti-pLDH drugs, particularly ones that are effective against P. falciparum, the most virulent species of human malaria. Our present work used docking studies to select potential inhibitors of pLDH, which were then tested for antimalarial activity against P. falciparum in vitro and P. berghei malaria in mice. A virtual screening in DrugBank for analogs of NADH (an essential cofactor to pLDH) and computational studies were undertaken, and the potential binding of the selected compounds to the PfLDH active site was analyzed using Molegro Virtual Docker software. Fifty compounds were selected based on their similarity to NADH. The compounds with the best binding energies (itraconazole, atorvastatin and posaconazole) were tested against P. falciparum chloroquine-resistant blood parasites. All three compounds proved to be active in two immunoenzymatic assays performed in parallel using monoclonals specific to PfLDH or a histidine rich protein (HRP2). The IC(50) values for each drug in both tests were similar, were lowest for posaconazole (<5 µM) and were 40- and 100-fold less active than chloroquine. The compounds reduced P. berghei parasitemia in treated mice, in comparison to untreated controls; itraconazole was the least active compound. The results of these activity trials confirmed that molecular docking studies are an important strategy for discovering new antimalarial drugs. This approach is more practical and less expensive than discovering novel compounds that require studies on human toxicology, since these compounds are already commercially available and thus approved for human use.
Keywords
Antimalarials/pharmacologyAntimalarials/therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemistry
Itraconazole/pharmacology
Share